Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles

Wagner, Sylvia; Rothweiler, Florian; Anhorn, Marion G.; Sauer, Daniel; Riemann, Iris; Weiss, Eike C.; Katsen-Globa, Alisa; Michaelis, Martin; Cinatl, Jindrich; Schwartz, Daniel; Kreuter, Jörg; Briesen, Hagen von; Langer, Klaus

doi:10.1016/j.biomaterials.2009.11.093

Cited by 131 publications

(50 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mAbs such as DI17E6 and cetuximab can recognize the EGFR [97,98]. The thiolated antibody (DI17E6) was covalently bound to the surface of HSA NPs and loaded with DOX.…”

Section: Modification and Targeting Of Albumin Npsmentioning

confidence: 99%

“…The thiolated antibody (DI17E6) was covalently bound to the surface of HSA NPs and loaded with DOX. The targeted vehicle showed specific targeting and cytotoxicity to EGFR-positive melanoma cells [98]. Löw et al prepared cetuximab-modified HSA NPs and tested them against EGFR-overex-pressing colon carcinoma cells [97].…”

Section: Modification and Targeting Of Albumin Npsmentioning

confidence: 99%

See 1 more Smart Citation

Albumin nanostructures as advanced drug delivery systems

Karimi

Bahrami

Ravari

et al. 2016

Expert Opinion on Drug Delivery

311

190

View full text Add to dashboard Cite

Introduction One of the biggest impacts that the nanotechnology has made on medicine and biology, has been in the area of drug delivery systems (DDSs). Many drugs suffer from serious problems concerning insolubility, instability in biological environments, poor uptake into cells and tissues, suboptimal selectivity for targets and unwanted side effects. Nanocarriers can be designed as DDSs to overcome many of these drawbacks. One of the most versatile building blocks to prepare these nanocarriers is the ubiquitous, readily available and inexpensive protein, serum albumin. Areas covered This review covers the use of different types of albumin (human, bovine, rat, and chicken egg) to prepare nanoparticle and microparticle-based structures to bind drugs. Various methods have been used to modify the albumin structure. A range of targeting ligands can be attached to the albumin that can be recognized by specific cell receptors that are expressed on target cells or tissues. Expert opinion The particular advantages of albumin used in DDSs include ready availability, ease of chemical modification, good biocompatibility, and low immunogenicity. The regulatory approvals that have been received for several albumin-based therapeutic agents suggest that this approach will continue to be successfully explored.

show abstract

“…mAbs such as DI17E6 and cetuximab can recognize the EGFR [97,98]. The thiolated antibody (DI17E6) was covalently bound to the surface of HSA NPs and loaded with DOX.…”

Section: Modification and Targeting Of Albumin Npsmentioning

confidence: 99%

Section: Modification and Targeting Of Albumin Npsmentioning

confidence: 99%

Albumin nanostructures as advanced drug delivery systems

Karimi

Bahrami

Ravari

et al. 2016

Expert Opinion on Drug Delivery

311

190

View full text Add to dashboard Cite

show abstract

“…Antibodies and peptides that block the function of α v β 3 and α v β 5 integrins have been shown to inhibit neovascularization in several in vivo models of pathological angiogenesis in mice [186,188]. HSA NPs containing DOX were conjugated with a MAb directed against α v integrins (DI17E6) using a heterobifunctional NHS-PEG-maleimid linker after MAb thiolation [189]. The produced NPs have shown the ability to specific target α v β 3 integrin positive melanoma cells and an increased cytotoxic activity in α v β 3 positive melanoma cells than the free drug.…”

Section: Vascular Endothelial Growth Factor Receptor (Vegfr)mentioning

confidence: 99%

Antibody-Conjugated Nanoparticles for Therapeutic Applications

Cardoso

Peça²,

Roque³

2012

CMC

110

View full text Add to dashboard Cite

Abstract:A great challenge to clinical development is the delivery of chemotherapeutic agents, known to cause severe toxic effects, directly to diseased sites which increase the therapeutic index whilst minimizing off-target side effects. Antibody-conjugated nanoparticles offer great opportunities to overcome these limitations in therapeutics. They combine the advantages given by the nanoparticles with the ability to bind to their target with high affinity and improve cell penetration given by the antibodies. This specialized vehicle, that can encapsulate several chemotherapeutic agents, can be engineered to possess the desirable properties, allowing overcoming the successive physiological conditions and to cross biological barriers and reach a specific tissue or cell. Moreover, antibody-conjugated nanoparticles have shown the ability to be internalized through receptor-mediated endocytosis and accumulate in cells without being recognized by the P-glycoprotein, one of the main mediators of multi-drug resistance, resulting in an increase in the intracellular concentration of drugs. Also, progress in antibody engineering has allowed the manipulation of the basic antibody structure for raising and tailoring specificity and functionality. This review explores recent developments on active drug targeting by nanoparticles functionalized with monoclonal antibodies (polymeric micelles, liposomes and polymeric nanoparticles) and summarizes the opportunities of these targeting strategies in the therapy of serious diseases (cancer, inflammatory diseases, infectious diseases, and thrombosis).

show abstract

“…It is useful to characterize and separate (purify) nanomaterials with different properties, dispersed in an aqueous solution. For example, it has been useful to separate antibody-conjugated nanoparticles from the free Rapid and simple Need of a labelling tag Sapsford et al [9] Rebolj et al [26] 3 International Journal of Polymer Science antibody and nanoparticles [22,23]. Another example of its use is the characterization of the molecular weight of nanoobjects, such as proteins or polymers [24].…”

Section: Size Exclusion Chromatography (Sec)mentioning

confidence: 99%

Analytical Methods to Characterize and Purify Polymeric Nanoparticles

Fornaguera

Solans

2018

International Journal of Polymer Science

View full text Add to dashboard Cite

Advances in polymeric nanoparticles as novel nanomedicines have opened a new class of diagnostic and therapeutic tools for many diseases. However, although the benchtop research studies in the nanoworld are numerous, their translation to currently marketed products is still limited. This lack of transference can be attributed, among other factors, to problems with nanomedicine characterization. Characterization techniques at the nanoscale could be divided in three categories: characterization of physicochemical properties (e.g., size and surface charge), characterization of nanomaterials interactions with biological components (e.g., proteins from the blood), and analytical characterization and purification methods. Currently available literature of this last group only describes methodologies applied for a specific type of nanomaterial or even methods used for bulk materials, which are not completely applicable to nanomaterials. For this reason, the current review aims to become a scholastic guide for those scientists starting in the nanoworld, giving them a description of analytical characterization techniques aimed to analyze polymers forming nanoparticles and possible forms to purify them before being used in preclinical and clinical applications.

show abstract

Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles

Cited by 131 publications

References 39 publications

Albumin nanostructures as advanced drug delivery systems

Albumin nanostructures as advanced drug delivery systems

Antibody-Conjugated Nanoparticles for Therapeutic Applications

Analytical Methods to Characterize and Purify Polymeric Nanoparticles

Contact Info

Product

Resources

About